CRF Health's TrialMax ePRO Instrument Achieves Validation Standard
CRF Health, the developer of the TrialMax® Suite of electronic Clinical Outcome Assessment Solutions (eCOA) for the life sciences industry, becomes the first eCOA company to complete a full validation study for Professor Juniper’s ACQ and AQLQ questionnaires to the “Gold Standard” based on her recently released “Levels of Acceptability of Electronic Versions” rating system. CRF Health continually collaborates with instrument authors to achieve the highest level of compliance with their instruments to assure data integrity.
CRF Health has now deployed spirometer integration together with the ACQ and AQLQ in several global studies on TrialMax Touch™ and TrialMax Slate™ with four major Pharmaceutical companies. Including these programs, CRF Health’s clinical reach and breadth using Professor Juniper’s instruments spans nearly 40 countries, 3000 patients, and more than 40 languages. In addition to these, CRF Health has deployed a further 15 studies using Professor Juniper’s ACQ and AQLQ instruments (but without spirometer integration).
TrialMax® solutions are available for 5 platforms including Windows, Windows Mobile, Android, Palm OS and Web, thus allowing clients to select the right platform, technology and hardware to support their clinical trials. The combination of CRF Health’s clinical expertise and innovation of ePRO collection methods, combined with patient engagement and retention tools, offer new ways to improve study execution and subject compliance.
In a recent study discussion, Professor Elizabeth Juniper commented, “I feel it is important, when evaluating a new technology device to determine whether it will give valid data, to keep in mind that validity is more likely to be achieved if the screen shots are similar to the original format especially when translating languages with longer text.”
“Professor Elizabeth Juniper’s diligence and research integrity is a model for the industry. We are excited to have had the opportunity to collaborate and to jointly achieve this industry milestone. It is through our engagement with researchers and instrument authors such as Professor Elizabeth Juniper that we continually enhance our regulatory rigor, technology competence and patient research integrity through clinical expertise and innovation,” commented Rachael Wyllie, CEO of CRF Health.
Related Links:
CRF Health’s TrialMax ePRO is Recognized as Medical Device
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Optimizing Phase III Oncology Trial Recruitment with Data-Driven Insights
February 3rd 2025A pharmaceutical company aimed to launch a Phase III clinical trial for a new oncology drug, focusing on efficient and effective patient recruitment across diverse regions. They evaluated patient populations by analyzing demographics, social determinants of health, and geography. Investigator profiling included practice details, affiliations, referral networks, and clinical trial experience. The final step involved selecting and extracting target lists for implementation.
